ICMR defends move to fast-track clinical trial of COVID-19 vaccine; Says process is in accordance with globally accepted norms

Indian Council of Medical Research (ICMR) has asserted that it is acting in accordance with the globally accepted norms to fast-track vaccine development for diseases of pandemic potential. It said, it is important to promote indigenous vaccine development while ensuring safety, quality, ethics and adherence to all regulatory requirement.

ICMR and Bharat Biotech have joined hands for the development of potential COVID-19 vaccine called Covaxin. The Drugs Controller General of India has accorded permission to conduct phase-1 and 2 human clinical trial.

ICMR said, in the larger public health interest, it is important for ICMR to expedite the clinical trials with a promising indigenous vaccine.